Digbi Health

Digbi Health treats cardiometabolic disease by combining precision biology—genetics, gut microbiome, continuous glucose and metabolic signals—with AI-driven multi-omic models and a coordinated clinical delivery system to personalize nutrition, pharmacotherapy (including GLP-1), and longitudinal coaching for durable outcomes. The platform integrates at-home DNA and microbiome testing, continuous glucose monitoring, and AI/bioinformatics that map biomarkers to metabolic pathways and predict treatment response. Digbi builds one unified care plan—nutrition, pharmacogenomics, medications and coaching—across obesity, type 2 diabetes, hypertension, dyslipidemia and related GI/mental-health comorbidities, delivered via remote intake, at-home kits, app-based meal/symptom tools, clinician oversight and EHR/lab integrations. For GLP-1 and pharmacotherapy, Digbi leverages a proprietary 140-biomarker “Tapering Success Predictor” plus pharmacogenomic and microbiome signals to target therapy, manage GI side-effect risk, and enable safe de-escalation, with flexible fulfillment options (direct-to-patient, PBM). The approach is evidence-based—trained on ~40K people/40B data points—and validated in peer-reviewed and payer pilots (Blue Shield subgroup: ~8.9% average weight loss and ~1.0% A1c reduction), delivering measurable clinical and financial ROI.